Tags

Type your tag names separated by a space and hit enter

Emerging treatment for chronic migraine and refractory chronic migraine.
Expert Opin Emerg Drugs 2012; 17(3):393-406EO

Abstract

INTRODUCTION

Chronic migraine (CM), the suffering of 15 or more headache days with at least 8 of these migraine days, afflicts 1.3% - 5.1% of the global population. CM is the most common disorder faced by experts in tertiary headache centers. When resistant to conventional medical treatment and prophylactic medication this condition is known as refractory chronic migraine (RCM). RCM is one of the greatest challenges in headache medicine.

AREAS COVERED

State-of-the-art and future medical treatments of chronic migraine include: OnabotulinumtoxinA, antiepileptic drugs (Levetiracetam, Magnesium valproate hydrate, Lacosamide, BGG-492), 5-HT agonists (Lasmiditan, NXN-188, novel delivery systems of Sumatriptan, a well-established drug treatment for acute migraine), CGRP receptor antagonists (BMS-927711), ML-1 agonists (Ramelteon), orexin receptor antagonist (MK-6096), plant-derived compound (LLL-2011) and other multitarget drugs such as Tezampanel, Tonabersat, intranasal carbon dioxide and BOL-148. The role for neuromodulation, the application of targeted electrical stimulation, will be examined.

EXPERT OPINION

Medication overuse headache (MOH) is now recognized to be a major factor in many cases of both chronic and refractory chronic migraine. MOH must be addressed prior to evaluating the effectiveness of new preventative and prophylactic treatment approaches. Innovative new drugs and electrical neuromodulation are promising CM treatments. Future studies must carefully screen patients and acquire data that can lead to personalized, tailored treatment strategies.

Authors+Show Affiliations

Sapienza University and Advanced Molecular Diagnostic Unit, Sant'Andrea Hospital, NESMOS Department, Rome, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

22862686

Citation

Lionetto, Luana, et al. "Emerging Treatment for Chronic Migraine and Refractory Chronic Migraine." Expert Opinion On Emerging Drugs, vol. 17, no. 3, 2012, pp. 393-406.
Lionetto L, Negro A, Palmisani S, et al. Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opin Emerg Drugs. 2012;17(3):393-406.
Lionetto, L., Negro, A., Palmisani, S., Gentile, G., Del Fiore, M. R., Mercieri, M., ... Martelletti, P. (2012). Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opinion On Emerging Drugs, 17(3), pp. 393-406. doi:10.1517/14728214.2012.709846.
Lionetto L, et al. Emerging Treatment for Chronic Migraine and Refractory Chronic Migraine. Expert Opin Emerg Drugs. 2012;17(3):393-406. PubMed PMID: 22862686.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Emerging treatment for chronic migraine and refractory chronic migraine. AU - Lionetto,Luana, AU - Negro,Andrea, AU - Palmisani,Stefano, AU - Gentile,Giovanna, AU - Del Fiore,Maria Rosaria, AU - Mercieri,Marco, AU - Simmaco,Maurizio, AU - Smith,Thomas, AU - Al-Kaisy,Adnan, AU - Arcioni,Roberto, AU - Martelletti,Paolo, Y1 - 2012/08/03/ PY - 2012/8/7/entrez PY - 2012/8/7/pubmed PY - 2013/1/15/medline SP - 393 EP - 406 JF - Expert opinion on emerging drugs JO - Expert Opin Emerg Drugs VL - 17 IS - 3 N2 - INTRODUCTION: Chronic migraine (CM), the suffering of 15 or more headache days with at least 8 of these migraine days, afflicts 1.3% - 5.1% of the global population. CM is the most common disorder faced by experts in tertiary headache centers. When resistant to conventional medical treatment and prophylactic medication this condition is known as refractory chronic migraine (RCM). RCM is one of the greatest challenges in headache medicine. AREAS COVERED: State-of-the-art and future medical treatments of chronic migraine include: OnabotulinumtoxinA, antiepileptic drugs (Levetiracetam, Magnesium valproate hydrate, Lacosamide, BGG-492), 5-HT agonists (Lasmiditan, NXN-188, novel delivery systems of Sumatriptan, a well-established drug treatment for acute migraine), CGRP receptor antagonists (BMS-927711), ML-1 agonists (Ramelteon), orexin receptor antagonist (MK-6096), plant-derived compound (LLL-2011) and other multitarget drugs such as Tezampanel, Tonabersat, intranasal carbon dioxide and BOL-148. The role for neuromodulation, the application of targeted electrical stimulation, will be examined. EXPERT OPINION: Medication overuse headache (MOH) is now recognized to be a major factor in many cases of both chronic and refractory chronic migraine. MOH must be addressed prior to evaluating the effectiveness of new preventative and prophylactic treatment approaches. Innovative new drugs and electrical neuromodulation are promising CM treatments. Future studies must carefully screen patients and acquire data that can lead to personalized, tailored treatment strategies. SN - 1744-7623 UR - https://www.unboundmedicine.com/medline/citation/22862686/Emerging_treatment_for_chronic_migraine_and_refractory_chronic_migraine_ L2 - http://www.tandfonline.com/doi/full/10.1517/14728214.2012.709846 DB - PRIME DP - Unbound Medicine ER -